"The Seby B. Jones Regional Cancer Center, consisting of medical oncology and radiation oncology, opened in 1993 on the Watauga Medical Center campus. The Cancer Center offers a multidisciplinary approach to the prevention, diagnosis and treatment of cancers. Through advanced technology and a highly trained staff, the Center offers exceptional diagnostic and treatment procedures that include radiation, chemotherapy, biotherapy, immunotherapy, prostate brachytherapy and hormonal treatments, including IMRT and IGRT. The Cancer Center also has an active focus on patient financial, clinical and psychosocial navigation by and expert clinical team."

During the past decade, Seby B. Jones Cancer Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Seby B. Jones Cancer Center" #1 collaborator was "Bayer" with 1 trials as a collaborator, "Cephalon" with 1 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Seby B. Jones Cancer Center" are "Lymphoma" (2 trials), "Chronic Myeloproliferative Disorders" (1 trials), "Cognitive/Functional Effects" (1 trials), "Colorectal Cancer Metastatic" (1 trials) and "Diffuse Large B-Cell Lymphoma" (1 trials). Many other conditions were trialed in "Seby B. Jones Cancer Center" in a lesser frequency.

Most popular intervention types in "Seby B. Jones Cancer Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bendamustine" (1 trials), "FOLFIRI" (1 trials), "Placebo" (1 trials), "Regorafenib (BAY 73-4506)" (1 trials) and "Rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Seby B. Jones Cancer Center" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Seby B. Jones Cancer Center". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Seby B. Jones Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Seby B. Jones Cancer Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".